RT Journal Article
SR Electronic
T1 Association of <em>Streptococcus mutans</em> harboring bona-fide collagen binding proteins and <em>Candida albicans</em> with early childhood caries recurrence
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.28.21252629
DO 10.1101/2021.02.28.21252629
A1 Garcia, B.A.
A1 Acosta, N.C.
A1 Tomar, S.L.
A1 Roesch, L.F.W.
A1 Lemos, J.A.
A1 Mugayar, L.C.F.
A1 Abranches, J.
YR 2021
UL http://medrxiv.org/content/early/2021/03/02/2021.02.28.21252629.abstract
AB Early childhood caries (ECC) recurrence occurs in approximately 40% of treated cases within one year. The association of Streptococcus mutans and Candida albicans with the onset of ECC is well known. Also, S. mutans strains harboring collagen-binding proteins (Cbps) avidly bind to collagen-rich dentin and are linked to increased caries incidence. Here, we investigated the presence of Cbp+ S. mutans and C. albicans in saliva and dental plaque of children with varying caries statuses, as well as the salivary microbiome of these children. In this cross-sectional study, 143 children who were caries-free, treated for ECC with no signs of recurrence after 6 months, or treated for ECC and experiencing recurrence within 6 months following treatment were enrolled. Co-infection with C. albicans and S. mutans, especially Cbp+ S. mutans, was strongly associated with caries recurrence. Subjects of the recurrence group infected with Cbp+ S. mutans showed a greater burden of C. albicans and of Mutans streptococci in dentin than those infected with Cbp− S. mutans. Microbiome analysis revealed that Streptococcus parasanguinis was overrepresented in the caries recurrence group. Our findings indicate that Cbp+ S. mutans and C. albicans are intimately associated with caries recurrence, contributing to the establishment of recalcitrant biofilms.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by DE022559, 5R90DE022530-09 and Colgate-Palmolive CARE awardAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The human subjects protocol was reviewed and approved by the Institutional Review Board of the University of Florida (IRB201600851)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll strains are available upon request. The Raw sequences were deposited in the Sequence Read Archive (SRA) BioProject (accession number PRJNA679743).